Skip to main content
. 2021 Jul 16;30(1):400–414. doi: 10.1016/j.ymthe.2021.07.004

Figure 2.

Figure 2

Cardiac-specific overexpression of ADAR2 protects AMI in mice hearts

(A) The schedule of virus injection and AMI model establishment. (B) Quantitative real-time PCR testing expression of ADAR2 after overexpression of ADAR2 by injecting AAV9-cTnT-ADAR2 with or without (AMI) surgery (n = 7:8:9:8, ∗∗p < 0.01). (C) Triphenyltetrazolium chloride (TTC) staining of mice hearts treated with AAV9-cTnT-ADAR2 followed by AMI; infarct size is indicated by IS (infarct size)/AAR (area at risk) (n = 7, ∗∗p < 0.01). (D) TUNEL staining (green) together with α-actinin (red) and DAPI (blue) of mice hearts treated with AAV9-cTnT-ADAR2 or AAV9-cTnT-ctrl followed by AMI (n = 6, ∗∗p < 0.01); scale bar, 20 μm. (E) Western blot of Bax, Bcl2, caspase 3, and cleaved-caspase 3 of the mice hearts treated with AAV9-cTnT-ADAR2 followed by AMI (n = 3, ∗∗p < 0.01). (F) Serum levels of LDH in indicated groups (n = 7:10:8:7, ∗∗p < 0.01). (G) Representative images of PI staining and quantification of the PI+ nuclei in the mice hearts treated as indicated (n = 6, ∗∗p < 0.01); scale bar, 20 μm. (H) Representative images of immunofluorescence staining and quantification of the 5-ethynyl-2′-deoxyuridine+ (EdU+) cardiomyocytes in the mice hearts treated as indicated (n = 6, ∗∗p < 0.01); scale bar, 20 μm. (I) Representative images of immunofluorescence staining and quantification of the Ki67+ and pHH3+ cardiomyocytes in the mice hearts treated as indicated (n = 6, ∗∗p < 0.01); scale bar, 20 μm. AMI, acute myocardial infarction; Ctrl, control; LDH, lactate dehydrogenase. ns, non-statistically significant.